TNFRSF11A and early-onset autosomal dominant Alzheimer disease: Because FEO function is maintained through advanced age58, 59, it might represent a valuable therapeutic target to slow progression of Alzheimer’s disease in cases where LEO impairment is suspected to accelerate cognitive decline.